Last reviewed · How we verify
Lipoplus + Omegaven — Competitive Intelligence Brief
marketed
Intravenous lipid emulsion
Nutrition support / Critical care
Small molecule
Live · refreshed every 30 min
Target snapshot
Lipoplus + Omegaven (Lipoplus + Omegaven) — General University Hospital, Prague. Lipoplus + Omegaven is a combination intravenous lipid emulsion that provides essential fatty acids and omega-3 polyunsaturated fatty acids for parenteral nutrition support.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lipoplus + Omegaven TARGET | Lipoplus + Omegaven | General University Hospital, Prague | marketed | Intravenous lipid emulsion | ||
| ClinOleic + Omegaven | ClinOleic + Omegaven | General University Hospital, Prague | marketed | Intravenous lipid emulsion |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Intravenous lipid emulsion class)
- General University Hospital, Prague · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lipoplus + Omegaven CI watch — RSS
- Lipoplus + Omegaven CI watch — Atom
- Lipoplus + Omegaven CI watch — JSON
- Lipoplus + Omegaven alone — RSS
- Whole Intravenous lipid emulsion class — RSS
Cite this brief
Drug Landscape (2026). Lipoplus + Omegaven — Competitive Intelligence Brief. https://druglandscape.com/ci/lipoplus-omegaven. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab